An Open-label Extension Study Evaluating the Safety and Efficacy of Upadacitinib (ABT-494) in Rheumatoid Arthritis Subjects
Status:
Completed
Trial end date:
2021-07-29
Target enrollment:
Participant gender:
Summary
This is a Phase 2, multicenter, open-label extension study in RA subjects. The sub-study is
to assess the impact of upadacitinib treatment (15 mg QD and 30 mg QD) with background MTX on
immunological responses to Prevnar 13® in RA patients.